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A DOUBLE-MASKED, RANDOMIZED,
SHAM-CONTROLLED, SINGLE-CENTER
STUDY WITH PHOTOBIOMODULATION
FOR THE TREATMENT OF DRY AGE-
RELATED MACULAR DEGENERATION
SAMUEL N. MARKOWITZ,* ROBERT G. DEVENYI,*† MARION R. MUNK,‡ CINDY L. CROISSANT,§
STEPHANIE E. TEDFORD,§ RENE RÜCKERT,¶ MICHAEL G. WALKER,** BEATRIZ E. PATINO,*
LINA CHEN,* MONICA NIDO,* CLARK E. TEDFORD§
Purpose: The LIGHTSITE I study investigated the efficacy and safety of photo-
biomodulation (PBM) treatment in subjects with dry age-related macular degeneration.
Methods: Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System,
wherein subjects underwent two series of treatments (3· per week for 3–4 weeks) over 1
year. Outcome measures included best-corrected visual acuity, contrast sensitivity, micro-
perimetry, central drusen volume and drusen thickness, and quality of life assessments.
Results: Photobiomodulation-treated subjects showed a best-corrected visual acuity
mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1)
and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement
of $5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects ($5-
letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treat-
ment (P , 0.01) and exhibited earlier stages of age-related macular degeneration disease.
Statistically significant improvements in contrast sensitivity, central drusen volume, central
drusen thickness, and quality of life were observed (P , 0.05). No device-related adverse
events were reported.
Conclusion: Photobiomodulation treatment statistically improved clinical and anatom-
ical outcomes with more robust benefits observed in subjects with earlier stages of dry age-
related macular degeneration. Repeated PBM treatments are necessary to maintain
benefits. These pilot findings support previous reports and suggest the utility of PBM as
a safe and effective therapy in subjects with dry age-related macular degeneration.
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Age-related macular degeneration (AMD) is a retinaldisease that results in irreversible, severe loss of
vision, including legal blindness. Disease progression
inevitably leads to significant visual dysfunction and
serious compromises in quality of life (QoL). The
prevalence of AMD is projected to affect 196 million
by the year 2020 with an expected growth rate to 288
million in 2040.1
Progression of AMD is characterized by accumula-
tion of membranous debris, lipofuscin, and extracel-
lular material and complement deposition. The
advanced late-stage dry form of AMD, which accounts
for 80% to 90% of the cases, is characterized by retinal
pigment epithelium (RPE) and outer retinal atrophy,
whereas only 10% to 20% develop the exudative, wet
late-stage form, with choroidal neovascularization
(CNV) as a hallmark of respective disease.2 Contrib-
uting factors to RPE cell degeneration include mito-
chondrial dysfunction, oxidative stress, inflammation,
and genetic disposition.3
Treatment is available for wet AMD through
periodic intravitreal injections of anti–vascular endo-
thelial growth factor compounds. The more frequent
dry form of AMD has limited treatment options
available other than lifestyle changes and the use of
vitamin supplements, demonstrating a significant
unmet clinical need for alternate treatment plans for an
expanding population base.4,5
1
The use of photobiomodulation (PBM), previously
termed low-level light therapy, involves targeted use
of selected wavelengths of visible light to near infrared
(NIR) light (500–1,000 nm) produced by a laser or
a noncoherent light source such as light-emitting di-
odes. Photobiomodulation can be applied to selected
tissues to produce beneficial cellular effects leading to
improved outcomes at the cellular, systemic, and clin-
ical level in a wide range of disease states.6–9 The
driving mechanism behind these benefits suggests that
the mitochondrial enzyme cytochrome C oxidase is
a key photoacceptor of light in the far red to NIR
spectral range.10–13 The beneficial effects of PBM
are linked to increases in mitochondrial energy gener-
ation through ATP, replication, density, and activity
and increases in RNA and protein synthesis.14
The use of PBM in ocular diseases and disorders has
been studied in both preclinical and clinical settings. In
animal models of ocular injury, PBM has reduced
damage or symptoms associated with methanol-
toxicity, laser burn, complement factor H knockout
inflammatory, bright light damage, retinitis pigmento-
sa, and diabetic retinopathy.15–19 Limited clinical stud-
ies show high potential for the use of PBM in the
ocular field. Ivandic and Ivandic20 have shown clinical
improvements in patients with amblyopia, retinitis pig-
mentosa, and AMD after treatment with PBM.20–22 In
subjects with AMD, treatment with a laser diode
aimed at the macular area improved visual acuity in
both subjects with dry and wet AMD. No changes in
visual acuity were seen in the control group, and there
were no reports of any adverse effects among PBM-
treated patients.20 Most recently, the Toronto and Oak
Ridge PBM Studies for Dry Age-Related Macular
Degeneration (TORPA I and II) presented evidence
for clinical (improvements in best-corrected visual
acuity [BCVA] and contrast sensitivity [CS]) and ana-
tomical (reductions in drusen volume) benefits after
PBM in patients with dry AMD.23,24 These positive
clinical findings coupled with the known
mitochondrial-based mode of action of PBM and the
underlying pathology associated with AMD highly
suggest that PBM treatment could have a therapeutic
role in dry AMD, a condition that is characterized by
mitochondrial dysfunction, oxidative stress, and
inflammation within the RPE cell layer.
The current study further investigates the effects of
PBM treatment on subjects with dry AMD in a double-
masked, randomized, sham-controlled, parallel group,
single-center prospective design. The primary goal of
this study was to evaluate the efficacy and safety of
PBM in subjects with dry AMD using the Valeda
Light Delivery System, specifically designed for the
ophthalmological use of PBM.
Methods
Subject Selection and Setting
Subjects were eligible for trial enrollment if they
had dry AMD and were in Age-Related Eye Disease
Study (AREDS) categories 2 to 4 with BCVA scores
as determined by the Early Treatment Diabetic
Retinopathy Study (ETDRS) Visual Acuity chart with
a letter score between 50 and 85 (Snellen equivalent of
20/40 to 20/200). Subjects were excluded from
enrollment with previous/active wet AMD, with
a history of epilepsy, with cognitive impairment, other
significant retinal disease, or other significant disease.
Subjects could use AREDS vitamin supplementation;
however, no change in supplements 1 month before
the study and during the study trial was allowed. A
total of 40 subjects were screened for the study, of
which 30 subjects were randomized into the study.
Both eyes were included if inclusion criteria were met
in both eyes. Therefore, an adapted AREDS classifi-
cation was used, as each eye was individually assessed
for the presence of center involving geographic
atrophy (GA). Thus, the fellow eye was not automat-
ically deemed AREDS Category 4 if the other eye
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showed center involving GA. A total of 46 eyes were
treated and analyzed.
This study took place at a single site located in
Toronto, ON, Canada. This study was conducted in
compliance with the protocol, Good Clinical Practice
guidelines, Health Canada regulatory requirements,
and all other applicable regulatory requirements. This
study was performed in adherence to the guidelines of
the Declaration of Helsinki.
Study Design
This prospective study was conducted in a double-
masked, randomized, sham-controlled, parallel group
format at a single clinical site. Data were collected
during 24 visits over the course of the 1-year study
(Figure 1). Subjects with dry AMD who met the inclu-
sion criteria, had none of the exclusion criteria, and
gave their written informed consent underwent sham
or PBM treatment randomized at a 1:1 ratio. Subjects
underwent two treatment series during the course of
the study which consisted of sham or PBM treatments
three times per week for three weeks, initiated at base-
line and repeated at 6 months with subsequent follow-
up visits after each treatment series. A consort diagram
is provided in Figure 2. Subjects and study staff were
masked to the treatment.
Evaluated Parameters
Subjects were assessed for BCVA using the ETDRS
charts (Precision Vision) and CS at 1.5, 3, 6, 12, and
18 cycles per degree (Levels A–E) (FACT, Stereo
Vision Optec 6500) before and after treatment. Quality
of life was assessed using the visual function
questionnaire-25 (VFQ-25), and retinal sensitivity
was recorded using microperimetry C10-2 grid with
68 tested points (MAIA; Centervue).
All subjects were assessed with 20 · 20 high-speed
SD-OCT volume scans (Spectralis OCT; Heidelberg
Engineering, Heidelberg, Germany) consisting of 49
section scans each (118 mm distance between each
scan, 9 frames averaged) and with 2 central (one hor-
izontal and one vertical) 30° line scans 36 times
averaged at baseline and at selected visits for anatom-
ical changes. Fundus autofluorescence (FAF) imaging
with 488-nm wavelength (Spectralis OCT; Heidelberg
Engineering) was performed at the same visits. Sub-
sequent spectral domain optical coherence tomography
(SD-OCT) scans were performed using the TruTrack
follow-up function to allow for exact comparison of
retina and drusen volume.
An independent, masked imaging expert reviewed
OCT and FAF images to determine dry AMD etiology
and confirm inclusion/exclusion criterion. SD-OCTs
and FAF were analyzed for following parameters:
aligned mean central retinal thickness, aligned mean
retinal volume, GA lesion area, and aligned drusen
volume. The presence of reticular pseudodrusen,
refractile drusen, incomplete and complete outer
retinal atrophy, incomplete and complete RPE and
outer retinal atrophy (iRORA and cRORA [corre-
sponds to GA]), evidence of a CNV, (pseudo)vitelli-
form lesions and irregularity/disruption of the external
limiting membrane, ellipsoid zone, and interdigitation
zone were assessed based on a predefined grading
protocol.25
The size and growth of GA were quantitatively
assessed by 488-nm FAF, using the Region Finder
Analyser (Region Finder Software Heidelberg Engi-
neering; Heidelberg Engineering).26 The area of
homogenous hypoautofluorescence on the FAF images
at baseline and follow-up images was measured and
quantified by one independent masked grader.26 The
absolute GA lesion area was used to evaluate growth
rate independent of initial lesion size.27
Photobiomodulation Treatment
Subjects were treated with the LumiThera Valeda
Light Delivery System (Figure 3) which delivers three
distinct wavelengths in the yellow (590 nm), red (660
nm), and NIR (850 nm) range. The Valeda Light
Delivery System parameters are presented in Table
1. Masking of the study was accomplished through
the use of the sham (placebo) treatment which deliv-
ered a noneffective dose of the selected wavelengths.
The sham mode delivered an approximate 100x
Fig. 1. Diagram illustrating the
LIGHTSITE I clinical study
visit design. Subjects who met
the inclusion/exclusion criteria
at the screening and baseline
visits were enrolled into the
study. Subjects received two
series of PBM treatments (Tx1
and Tx2) with a total of 9
treatment sessions per series
distributed over 3 weeks to 4 weeks. Subjects underwent assessments at subsequent follow-up visits. The study comprised of 24 visits over the
course of 1 year.
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reduction in treatment fluence compared with the PBM
mode. The integrity of the masking of the treatment
modalities was further ensured through the inherent
design of the Valeda instrumentation. The perfor-
mance/output of all visible and audible indicators,
including the graphic user interface, was identical for
both treatment modalities (i.e., other than the emission
of visible and NIR PBM, the behavior of the system
was identical for both the sham and PBM treatment).
The Valeda device operator was further masked by
operating the instrument under a cloth shield to pre-
vent any accidental viewing of incidental light during
the treatments. The Valeda Light Delivery System is
an investigational device. The Valeda System is CE-
marked but not approved for use by the FDA or Health
Canada.
Statistical Analyses
Statistical analyses were performed using R
version 3.0 or higher (R: The R Project for Statis-
tical Computing; https://www.r-project.org/). All
analyses are based on individual eyes, rather than
individual subjects, unless otherwise indicated.
Fig. 2. LIGHTSITE I consort
diagram. Study subject progress
through each study phase.
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Linear mixed-effects (LME) analyses were performed
using the R package NLME. Graphs were generated
using the R package ggplot2. Best-corrected visual acu-
ity, CS, and microperimetry comparisons were analyzed
with a LME two-level hierarchical model, with eyes
nested within subject, to account for correlation between
eyes, with treatment group as a fixed effect and subject
as a random effect. Changes before and after PBM
within the PBM group and before and after sham within
the sham group were analyzed using a Wilcoxon signed-
rank test for paired data (significance set at P, 0.05). A
Wilcoxon rank-sum (Mann–Whitney U) test was used
to compare the difference between PBM-treated and
sham-treated subjects in changes at selected intervals.
The nonparametric (Wilcoxon) tests were not adjusted
for correlation between eyes within subject. VFQ-25
analysis used a linear regression model. Fisher’s exact
test was used to analyze AREDS category distribution
between treatment groups. Two-sided P values less than
0.05 were considered statistically significant. Adjust-
ments for multiple comparisons were not performed.
Analyses used the Intent to Treat (ITT) population,
unless otherwise specified. All 30 subjects and 46 eyes
randomized are included in the ITT population and the
ITT analyses. Linear mixed-effects models were used to
allow for the possibility of missing values at particular
time points in ITT analyses.
Results
The LIGHTSITE I study evaluated 30 subjects for
a total of 46 qualifying eyes. The mean age for all
subjects was 76 years (±8.3). A higher number of
women (60%) than men (40%) were included. The
median duration of dry AMD was 7.8 years (±7.6)
since diagnosis.
The majority of subjects had intermediate to
advanced stage dry AMD as categorized by high
prevalence of subjects with AREDS categories 3
(30.4%) and 4 (67.4%) (Table 2). The majority of eyes
had GA (73.9%). In the sham group, 52.9% of eyes
that were categorized as AREDS Category 4 with cen-
tral 1.0 mm involving GA also had foveola involve-
ment. In the PBM group, 78.5% of eyes that were
categorized as AREDS 4 with central 1.0 mm involv-
ing GA also had central foveola involvement. No sta-
tistical differences between the sham and PBM
treatment groups were seen in the distribution of
AREDS categories (Fisher’s exact test, P = 0.27). In
total, almost half (20/46 eyes, 43.5%) of all eyes in this
study were categorized as AREDS 4 with foveola
involving GA.
Best-Corrected Visual Acuity Assessment
Sham- and PBM-treated subjects had similar base-
line BCVA mean letter scores (sham, 71.9 ± 2.5;
PBM, 73.8 ± 1.9). In the ITT analysis, after the initial
treatment series at M1, sham subjects showed no sig-
nificant change from BL with a one-letter improve-
ment, whereas PBM-treated subjects showed an
increase in BCVA of 4 letters to 77.7 ± 2.5 letters
(Table 3). Photobiomodulation treatment effects on
BCVA appeared to start to diminish at the M6 time
point (76.1 ± 2.3 letters) just before retreatment. After
Table 1. Valeda Light Delivery System Specifications
Parameter Specifications
Light sources Light-emitting diodes
Light emission
(maximal)
590-nm output: 5 mW/cm2
660-nm output: 65 mW/cm2
850-nm output: 8 mW/cm2
Beam diameter 30 mm (nominal) at treatment plane
Treatment
exposure time
A total of 250 seconds (4 minutes 10
seconds). There are 4 phases:
1: 35 seconds, patient’s eyes
open [pulsed yellow and NIR
wavelengths]
2: 90 seconds, patient’s eyes
closed [continuous red
wavelength]
3: 35 seconds, patient’s eyes
open [pulsed yellow and NIR
wavelengths]
4: 90 seconds, patient’s eyes
closed [continuous red
wavelength]
Fig. 3. The Lumithera Valeda Light Delivery System. Illustration of the
Valeda front (left) and backside (right).
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the second series of PBM treatments at M7, PBM-
treated subjects’ mean BCVA improved to a letter
score of 78 ± 2.4. The PBM benefits diminished again
by M12 and returned to approximate prestudy BL
BCVA levels (74.2 ± 2.6 letters) (Figure 4). High
variability of BCVA changes across subjects sup-
ported additional analysis to further understand the
subjects’ individual responses.
Subsequent stratified analysis of the benefits of
PBM treatment demonstrated that 50% of PBM-
treated subjects showed improvement of 5 or more
letters (one-line improvement or better, Figure 5) com-
pared with only 13.6% of sham-treated subjects at M1.
Photobiomodulation-treated eyes were evaluated as
either low responders (LRs) (,5 letters at M1) or high
responders (HRs) ($5 letters at M1) to determine the
duration of benefit and if PBM treatment benefits were
associated with stage of disease. The HR and LR
groups were defined as a post hoc analysis. Responder
status is determined for each eye, rather than for each
subject. At each visit, within each group (HRs and
LRs), a paired t-test and a Wilcoxon signed-rank test
of BCVA change from baseline were performed. For
the course of 1 year, statistically significant benefits (P
, 0.05) were seen for the HR group at M1, M2, M3,
M7, and M9 (but not at visits M6 and M12), which
were immediately before retreatment and at the con-
clusion of the study at 12 months. The HR mean
BCVA benefit immediately after PBM was 8.0 letters
at M1 and 6.0 letters at M7 from BL. The LR eye
group did not show any significant benefits over the
course of the study.
These two groups were then analyzed for AREDS
stage and for foveola involving GA. Approximately
91.3% of HR eyes were either AREDS Category 3
with drusen only or noncentral 1 mm involving GA or
AREDS Category 4 with GA, involving the central
1 mm, but still sparing the foveola. By contrast, the LR
eyes were primarily AREDS Category 4 (11 of 12),
wherein 83.3% (10 of 12) had foveola involving GA.
Photobiomodulation-treated eyes were further strat-
ified by their BCVA-equivalent Snellen score at BL.
Table 2. Baseline Disease Distribution According to Age-Related Eye Disease Study Classification and Study Variables
Adapted AREDS Classification Sham (n, %) (n = 22 Eyes) PBM (n, %) (n = 24 Eyes)
AREDS Category 2 0, 0.0% 1, 4.2%
AREDS Category 3 5, 22.7% 9, 37.5%
AREDS Category 4 17, 77.3% 14, 58.3%
GA 18, 81.8% 16, 66.7%
RPD 14, 63.6% 13, 54.2%
Baseline Study Variable (Units) Sham (Mean ± SD) (n = 22 Eyes) PBM (Mean ± SD) (n = 24 Eyes)
Foveola involvement 9, 40.9% 11, 45.8%
ORA 2, 9.0% 5, 20.8%
iRORA 0, 0.0% 5, 20.8%
Refractile drusen 4, 18.2% 12, 50.0%
PR intact 0, 0.0% 2, 8.3%
Mean CRT (mm) 210.7 ± 78.7 241.5 ± 58.6
Mean RV (mm3) 7.8 ± 0.9 8.2 ± 0.7
Mean GA size (mm2) 7.5 ± 7.8 6.0 ± 5.7
End of Study Variable (Units) Sham (Mean ± SD) (n = 22 Eyes) PBM (Mean ± SD) (n = 24 Eyes)
ORA 2, 0.9% 4, 16.7%
iRORA 0, 0.0% 4, 16.7%
PR intact 0, 0.0% 2, 8.3%
Mean CRT (mm) 209.9 ± 91.4 229.4 ± 61.5
Mean RV (mm3) 7.7 ± 1.1 8.0 ± 0.8
Mean GA size (mm2) 7.8 ± 7.8 6.5 ± 6.4
CRT, central retinal thickness; iRORA, incomplete retinal pigment and outer retinal atrophy; ORA, outer retinal atrophy; PR,
photoreceptor; RPD, reticular pseudodrusen; RV, retinal volume.
Table 3. Best-Corrected Visual Acuity Outcomes
Throughout 12-Month Time Course
BCVA M1 M2 M3 M6 M7 M9 M12
Sham (n = 22 eyes) 1.2 2.7 1.4 0.4 1.7 2.0 0.6
STD 5.4 6.5 6.0 5.4 6.0 6.9 5.5
SEM 1.4 1.8 5.4 1.4 6.2 1.8 1.5
Count 22 19 21 21 21 21 20
PBM (n = 24 eyes) 3.8 2.6 4.1 2.4 4.3 1.2 0.5
STD 5.1 5.6 5.4 5.5 6.2 7.4 8.4
SEM 1.3 1.5 1.5 1.4 1.6 1.9 2.2
Count 24 23 19 23 23 23 23
BCVA mean change from baseline across all time points.
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Three different groups were created and compared.
They were eyes with Snellen equivalent scores of 20/
200 (ETDRS BCVA letter score of 50) or greater,
Snellen 20/100 (ETDRS BCVA letter score of 65) or
greater, and Snellen 20/80 set (ETDRS BCVA letter
score of 70) or greater. The goal was to further define
the treatment response in the different patient groups
and to optimize inclusion/exclusion criteria for the
future clinical studies by evaluating HRs and LRs by
BL vision measurements. Of the LR eyes, 41.7% were
eliminated from the study population when the Snellen
cutoff was reduced to 20/100. The LR eyes were
further reduced to 50% when the Snellen cutoff was
further reduced to 20/80. The HR population was only
reduced to 91.7% at 20/80. The Snellen population
comparison suggests eyes that most significantly
respond to PBM treatment are eyes with remaining
good baseline vision at Snellen equivalents of 20/100
or better.
Contrast Sensitivity Assessment
Photobiomodulation-treated eyes showed statisti-
cally significant (Wilcoxon signed-rank test, P ,
0.05) improvement in CS at Level E (18 cycles/
degree) out to 12 months after treatment (Figure 6).
The increase in CS at M1 was 0.35 + 0.1 and was
maintained (0.30 + 0.11) at M12. The Level D (12
cycles/degree) CS data for the PBM-treated group
showed a positive trend in benefits over the first 6
months from BL, but the results were not statistically
significant (Wilcoxon signed-rank test, P = 0.45). The
Level B (3 cycles/degree) CS was significant at 12
months between the PBM-treated and sham groups,
P = 0.026, but not significant at any other time point.
Levels A (1.5 cycles/degree) and C (6 cycles/degree)
CS data for the PBM-treated group versus sham-
treated group were not statistically significant (Wilcox-
on signed-rank test, P . 0.05).
Microperimetry Assessment
No statistically significant reduction in bicurve
ellipse area measure fixation stability (FS) was
observed between PBM- or sham-treated subjects,
Fig. 4. The effect of PBM on ETDRS BCVA letter score over-time. As
a group, PBM-treated subjects showed an improvement in 4 letters
immediately after treatment (M1 and M7) which diminished over time
demonstrating the need for repeated treatment to maintain clinical
benefits.
Fig. 5. The percentage of PBM-treated subjects with a $5 letter
improvement on ETDRS visual acuity from baseline over time. After
each treatment series (M1 and M7), almost one half of all PBM-treated
eyes showed $5 letter gain (50% of eyes at M1, 46% of eyes at M7).
This effect was reduced over time until the next treatment series was
initiated. Photobiomodulation-treated eyes that showed $5 letter gain
were typically in earlier stages of the disease and did not have signifi-
cant GA with foveola involvement.
Fig. 6. The effect of PBM on contrast sensitivity (Level E, 18.0 CPD)
in LogCS change from baseline. Photobiomodulation-treated subjects
showed significant improvement in CS at Level E (18 cycles/degree)
out to 12 months after treatment, Wilcoxon signed-rank test, P , 0.05.
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LME model analysis (P . 0.05) at M1 or M12. How-
ever, the BL FS levels were higher in the PBM-
treatment group, and an improvement in FS after
PBM at M1 was seen from 4.4 ± 1.6 to 2.6 ± 0.6
degrees2 in the PBM-treatment group. Subsequently,
FS values increased in both the sham-treatment and
PBM-treatment group over time to reach levels of 4
to 6 before retreatment at M6. For the PBM group, FS
at M6 was 6.5 ± 4.0. After the PBM retreatment at M7,
the FS values again improved to a mean of 2.3 ± 0.7
degrees,2 whereas the sham-treatment group did not
respond (LME, P = 0.0041).
Quality of Life Assessment (VFQ-25)
The PBM-treated subjects demonstrated a statisti-
cally significant improvement in the QoL composite
score at M3 (P = 0.003), M7 (P = 0.015), and M9 (P =
0.003) (Wilcoxon signed-rank test) and select ques-
tions related to activities of daily living at M3, M7,
and M9. The sham group did not demonstrate a statis-
tically significant improvement (Wilcoxon signed-rank
test, P . 0.05) in any assessment.
Anatomical Assessments
Drusen volume increased over time in 100% of the
sham-treated subjects. By contrast, 70% of the PBM-
treated subjects showed a decrease in drusen volume.
A statistically significant reduction in drusen volume
at M12 (LME, P = 0.05) was observed in PBM-treated
subjects versus the sham-treated subjects (Figure 7).
No statistically significant difference in reduction in
the mean central 1-mm drusen thickness was observed
in PBM-treated subjects versus sham-treated subjects
at M12 (LME, P = 0.18) (Figure 8). Central 1-mm
drusen thickness decreased in all eyes, PBM versus
sham, and was significant at M7 (LME, P = 0.03).
No difference in terms of GA lesion growth in the
PBM-treated subjects compared with the sham-
treated subjects after treatment at 12 months was re-
corded (LME, P . 0.05). No statistically significant
change in retinal volume or central retinal thickness
was observed in the PBM- and sham-treated groups.
Safety Assessment
A total of 21 adverse events (AE) were reported
during the study (Table 4). In the sham group, 5 AEs
were reported by 4 subjects compared with 16 AEs
reported by seven subjects in the PBM group. One
subject in the PBM group had an eye convert to wet
AMD approximately 20 days after the baseline visit.
None of the AEs were considered by the investigator
to be related to the treatment.
Discussion
The LIGHTSITE I study was the first double-
masked, randomized, sham-controlled, parallel group
study to evaluate PBM in subjects with dry AMD. The
results from the study illustrate positive benefits after
PBM treatment in both clinical and anatomical out-
comes in subjects with dry AMD. These findings
corroborate and extend previous reports using the
same three wavelengths as delivered in the Valeda
Light Delivery System,23,24 demonstrating clinical
improvement in patients with dry AMD after PBM
therapy.
Significant improvements in BCVA and CS were
noted at various time points after treatment with PBM
throughout the 12-month study. Overall, a mean
increase of 4 letters in BCVA was observed at M1
immediately after the first series of treatments. This
was followed by a gradual decline in BCVA up to the
6-month mark where the second PBM series was set to
take place. The second PBM treatment series imme-
diately improved BCVA letter scores by approxi-
mately 4 letters, which similarly declined back to BL
levels by M12. These data suggest that PBM efficacy
will need to be maintained through repeated 4-month
to 6-month retreatment intervals to provide continuous
benefits. The molecular underpinnings that drive the
effectiveness of PBM make it unlikely that solitary
treatment sessions would demonstrate continuous
effects. Photobiomodulation dosing protocols com-
monly use repetitive maintenance doses, and repeated
Fig. 7. The effect of PBM on drusen volume (mm3) over time. Drusen
volume increased over time in 100% of the sham-treated subjects. By
contrast, 70% of all PBM-treated subjects showed a reduction in drusen.
A statistically significant reduction in drusen volume at M12 (LME, P =
0.05) was observed in PBM-treated subjects versus the sham-treated
subjects.
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PBM treatments have been suggested by other inves-
tigators to stabilize the initial improvements seen in
BCVA in other ocular disease states.22
Overall, 50% of the PBM-treated subjects showed
$5 letters improvement after the first series of treat-
ment, and 46% of PBM-treated subjects showed $5
letters improvement after the second series of treat-
ments. When looking at letter gain in this subject
cohort, a total improvement of 8 letters was observed
after the initial treatment series. This subject-specific
increase in BCVA letter gain after PBM treatment
warrants further investigation and suggests a potential
influence of individual disease pathology on the effi-
cacy of PBM treatment. Further exploration of the
pathological profile of the enrolled subjects showed
that most subjects were classified as AREDS Category
4 with central GA including foveola involvement.
Geographic atrophy with foveola involvement was
observed in 67.4% of the subjects. Stratifying eyes
by BCVA outcomes into those who were HRs (i.e.,
$5 letters improvement after the first series of treat-
ment at M1, HR) demonstrated that high responding
eyes were earlier in the disease stage. In the HR group,
66.7% were AREDS Category 3 and 75% had no GA.
Most telling was that 92% of the subjects in the HR
group had no GA with central foveola involvement. In
contrast, in the PBM-treated LR group (i.e., ,5 letters
of improvement at M1, LR), 83.3% were AREDS
Category 4 with GA and central foveola involvement.
As disease progression occurs, increased damage and
tissue loss are observed limiting the viable retinal tis-
sue that serves as a necessary substrate for PBM activ-
ity. Therefore, these findings show that subjects with
dry AMD in earlier stages of the disease are more
likely to respond better to PBM compared to subjects
with more advanced disease and extensive central
tissue loss. The high number of subjects with
advanced stage AMD contributed to the reduced over-
all benefits seen in BCVA letter score in the intent-to-
treat group analysis.
In addition to BCVA, assessments of CS and
microperimetry are suggested to be sensitive parame-
ters of visual function and are impaired at an earlier
disease stage. A significant improvement in CS at
Level E (18 cycles/degree) was observed immediately
after PBM treatment extending to M12. A trend was
Fig. 8. Representative example of anatomical improvement in a PBM-treated eye. This eye was categorized as AREDS 3. Baseline (top) imaging
illustrates drusen volume of 0.78 mm3 with a mean central 1-mm drusen thickness of 165 mm. Black numbers indicate the mean thickness of each
ETDRS subgrid, and red numbers indicate the corresponding volume (mm3). The maps on the left-hand side depict the color-coded drusen thickness
map. Month 12 (bottom) imaging illustrates an overall reduction in volume (0.41 mm3) and mean central thickness (18 mm) after PBM treatment.
Table 4. Adverse Events
Sham PBM
Serious adverse events (by
preferred term)
Large granular lymphocytosis 1 0
Total 1 0
Adverse events (by preferred term)
Atrial fibrillation 0 1
Conjunctival hemorrhage 1 0
Disorientation 0 1
Dry eye 0 1
Eye pain 0 1
Eye pruritus 0 2
Fatigue 1 0
Gastroesophageal reflux disease 0 1
Hematuria 0 1
Influenza 0 1
Insomnia 1 0
Lacrimation increased 0 1
Large granular lymphocytosis 1 0
Macular degeneration 1 0
Neovascular AMD 0 1
Photopsia 0 1
Vision blurred 0 2
Visual brightness 0 1
Vitreous floaters 0 1
Total 5 16
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also noted at Level D (12 cycles/degree) over the first
6 months from BL. Improvements in high performing
CS subjects support beneficial changes in visual
function, regardless of severity. Significant improve-
ments in FS (microperimetry) were also observed. The
combined efficacy of PBM to improve aspects of
BCVA, CS, and microperimetry supports the utility of
PBM on multiple visual function endpoints.
Functional endpoints such as BCVA and CS are
standardized clinical outcome measures for the assess-
ment of disease severity, progression, and response to
treatment.28 In AMD, improvements in BCVA have
become the gold standard for the assessment of effi-
cacy of new treatment options. This is largely attrib-
uted to clinical trials surrounding wet AMD where
pharmaceutical interventions are used to recover sig-
nificant acute vision loss through inhibition of neovas-
cularization. In the earlier stages of AMD and also in
GA with foveal sparing, the extent of visual dysfunc-
tion may remain stable or slowly decline over years
without rapid vision loss. Therefore, any visual gain in
this patient population, which has not experienced
rapid profound vision loss due to CNV, should be
considered clinically relevant.
The AREDS data show that about one-third of
patients have center-involving GA at the time of initial
GA diagnosis. For the remaining two-thirds, there was
a median time to progression from foveal sparing GA
to central GA of 2 years. Visual acuity is often
moderately decreased before the development of
central GA, and for those who do not develop CNV,
vision is expected to decline an additional 22 letters on
average over the next 5 years as soon as the foveal
center is involved. That is an equivalent to a loss of
approximately 4 letters per year. Eyes that develop
subsequent CNV have an even worse prognosis.29 A
recent study on dry AMD evaluated disease burden
and progression in a real-world setting among patients
from the United Kingdom with bilateral GA secondary
to AMD.30 Of the 523 patients who had visual acuity
follow-up and a level of visual acuity in their better-
seeing eye that would have placed them in a category
of eligible to drive at baseline, 349 (67%) became
ineligible to drive with a median time to progression
of 1.6 years. In the worse-seeing eye, mean visual
acuity decreased over 2 years and continued to decline
over 60 months. Mean loss of ETDRS letters from
baseline was 2.0 letters at Month 12, 6.1 letters at
Month 24, and 10.9 letters at Month 60. Over this
same timeframe, the better-seeing eye exhibited
a steeper trajectory of visual acuity loss; 5.7 letters,
12.4 letters, and 22.6 letters by months 12, 24, and 60,
respectively. Clinically meaningful vision loss
occurred in both the worse-seeing eye (6.1 letters)
and the better-seeing eye (12.4 letters), and the latter
rate was twice as rapid compared with the worse-
seeing eye. Therefore, we pose that the improvements
in BCVA observed in this study are of significance
and clinically relevant to this patient population af-
flicted by the earlier form of AMD.
The results from the LIGHTSITE I study also
revealed improvements in anatomical features such
as drusen volume and thickness. These findings are
consistent with other reports showing similar effects in
subjects with AMD after PBM.23 Early and interme-
diate AMD is characterized by the thickening of the
Bruch membrane due to the accumulation of lipid and
proteins, which form sub-RPE deposits called drusen.
Increase of amount of drusen is correlated to disease
progression and a risk factor for the development of
late complications of AMD including GA, CNV, and
subsequent central vision loss. Previous studies report
that the rate of progression to advanced AMD (CNV
and GA over 5 years) is 1.3% with many small or few
medium drusen, 18% if many medium or any large
drusen (AREDS, Category 3), and 43% if unilateral
advanced AMD is present.31,32 There are no approved
treatments that currently act to improve vision and
influence the hallmark pathology of the disease, so
the reductions in these key features of dry AMD are
of clinical interest. Sham-treated subjects showed an
increase in all eyes in drusen volume throughout the
study, whereas 70% of PBM-treated eyes showed
a reduction in drusen volume. Improvements in these
anatomical features may be correlated to delays in
disease progression. However, it should be noted that
long-term evidence is needed to correlate drusen
reduction with changes in disease progression. Histor-
ically, subthreshold laser therapy to reduce drusen has
not demonstrated improvements in clinical out-
comes.33 The Complications of Age-Related Macular
Degeneration Prevention Trial was conducted at 22
clinical centers involving 1,052 participants. Partici-
pants were observed for at least 5 years after laser
treatment. The results of this study provide no evi-
dence of a clinically significant beneficial or harmful
effect of preventive laser treatment in eyes with bilat-
eral large drusen at high risk of progression to late
AMD. A recent meta-analysis on 11 studies random-
izing 2,159 patients showed that laser treatment is
capable to reduce drusen volume (OR 9.16), but fails
to reduce the incidence of CNV (OR 1.07) or the loss
of three or more lines (OR 0.99) at a 2-year follow
up.34
The Complications of AMD Prevention trial, as well
as the meta-analysis, looked at laser and sub-threshold
laser, a different technique than PBM treatment, where
spot thermal laser applications were delivered to the
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retinal tissue.33,34 In the Complications of Age-Related
Macular Degeneration Prevention trial, the initial laser
treatment protocol specified 60 barely visible burns
applied to specific areas of the retina. At 12 months,
eyes assigned to treatment that had sufficient drusen
remaining were retreated. The key difference is the use
of PBM to stimulate retinal cellular function and not
the removal of drusen through cellular repair mecha-
nisms that occur after laser damage to the tissue (i.e.,
subthreshold). Photobiomodulation has very defined
cellular benefits that have been established in many
animal models. While differing treatment modalities,
PBM will require long-term follow-up to establish that
reductions in drusen are correlated to slowing of dis-
ease progression. Clinical benefit may not correlate to
drusen reduction, and in the current study, the clinical
outcomes were seen before significant reductions in
drusen. However, drusen pathology leads to further
disease progression, and drusen reduction may reflect
a shift from deposition to removal as cellular improve-
ments are seen after PBM.
Progressive vision loss is accompanied by a dimin-
ished QoL in patients with a diagnosis of AMD. A
validated patient questionnaire (VFQ-25) was used to
capture subject-reported improvement in QoL measures.
Photobiomodulation treatment provided a statistically
significant benefit over time, which was consistent with
other quantitative clinical outcome measures. Activities
of daily living scores were improved after PBM
treatment. This improvement is significant in its potential
to provide relief to patients. This relief may be measure-
able in regards to independence and lifestyle limitations
which threaten patients with AMD.
A limited number of AEs were reported throughout
the study demonstrating a favorable safety profile of
the treatment. A total of 21 AEs were reported during
the study by four sham subjects and seven PBM
subjects. One eye converted to wet AMD in the PBM-
treated group within 1 month of the study. The subject
was treated with intravitreal anti–vascular endothelial
growth factor injections in the respective eye and
followed with no further complications. Photo-
biomodulation treatment was continued for the dura-
tion of the study in the remaining dry AMD eye. The
dry AMD eye in this subject gained 22 letters by M12
after PBM treatments. The rate of conversion from dry
to wet in the current 1-year study was 1 of the 24
PBM-treated eyes for an incident rate of 4.2% or 1 of
46 eyes included in total for an overall incident rate of
2.2%. The published rate of progression to CNV was
recently reported as 7.4% per patient-year.30 None of
the ocular AEs were considered related to the device
by the principal investigator and common for the type
of disease treated.
There were various limitations to the study inherent
to the pilot nature, which include the small sample size
and single-center study. Future studies will evaluate
increased numbers of patients across multiple clinical
sites furthering the safety and efficacy data for PBM
treatment in dry AMD. This study enrolled a large
number of advanced stage patients. On stratification,
a decreased effect of PBM in this cohort of patients
was observed reducing the overall effect of PBM in all
subjects.
The LIGHTSITE I study suggests the utility of PBM
treatment for dry AMD. Clinically significant im-
provements after PBM treatment were observed in
BCVA and CS. Improvements in clinical outcomes
after PBM were more robustly seen in subjects with
earlier stage disease. In addition, improvements in
microperimetry and anatomical outcomes such as
drusen volume and drusen thickness were observed.
No device-related adverse events were reported dem-
onstrating a favorable safety profile of PBM in dry
AMD. These findings support previous reports and
demonstrate the potential utility of PBM in subjects
with dry AMD.
In conclusion, LIGHTSITE I was an exploratory
pilot study that suggested multiple clinical and ana-
tomical benefits after PBM treatment in subjects with
dry AMD. The clinical data support preclinical and
previous investigator-led clinical studies but herein
established in a prospective, randomized, sham-
controlled study on how to apply a multiwavelength
PBM treatment and gave insight into what patients to
target for best clinical results. Further work is planned
with multicenter trials with the Valeda Light Delivery
System. Most importantly, the LIGHTSITE I results
may pave the way for a new treatment approach
expanding the field of PBM into the ocular world to
combat a debilitating disease with limited patient
options. From a clinician standpoint, the treatment
may provide an option to their patients to address the
disease early, improve visual outcomes, and poten-
tially slow the progression of the disease. We know
from experience in other fields that addressing disease
early may have the most impact on patient QoL, health
care costs, and create the awareness for vision loss
prevention. As with most early studies, LIGHTSITE I
created additional questions and fostered new ideas
that will expand clinical research with PBM, which
will provide further insight into best practices for PBM
in fighting ocular disease.
Key words: dry age-related macular degeneration,
drusen, light-emitting diode, low-level light therapy,
photobiomodulation, vision loss, best-corrected visual
acuity, mitochondria, contrast sensitivity.
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